Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU®

CAMBRIDGE, MA / ACCESS Newswire / November 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that Health Canada has authorized mFLUSIVA® (Influenza mRNA vaccine; mRNA-1010) and mCOFLU® (Combined Influenza and COVID-19 mRNA vaccine; mRNA-1083) for adults 50 years of age and older. Canada is the first country in the world to authorize both Moderna's seasonal mRNA influenza vaccine and combination influenza and COVID-19 vaccine.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.